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Background. Neonatal encephalopathy (NE) is a leading cause of child mortality and longer-term impairment. Infection can 
sensitize the newborn brain to injury; however, the role of group B streptococcal (GBS) disease has not been reviewed. This paper 
is the ninth in an 11-article series estimating the burden of GBS disease; here we aim to assess the proportion of GBS in NE cases.
Methods. We conducted systematic literature reviews (PubMed/Medline, Embase, Latin American and Caribbean Health 
Sciences Literature [LILACS], World Health Organization Library Information System [WHOLIS], and Scopus) and sought unpub-
lished data from investigator groups reporting GBS-associated NE. Meta-analyses estimated the proportion of GBS disease in NE 
and mortality risk. UK population-level data estimated the incidence of GBS-associated NE.
Results. Four published and 25 unpublished datasets were identified from 13 countries (N = 10 436). The proportion of NE asso-
ciated with GBS was 0.58% (95% confidence interval [CI], 0.18%–.98%). Mortality was significantly increased in GBS-associated NE 
vs NE alone (risk ratio, 2.07 [95% CI, 1.47–2.91]). This equates to a UK incidence of GBS-associated NE of 0.019 per 1000 live births.
Conclusions. The consistent increased proportion of GBS disease in NE and significant increased risk of mortality provides 
evidence that GBS infection contributes to NE. Increased information regarding this and other organisms is important to inform 
interventions, especially in low- and middle-resource contexts.
Keywords. group B Streptococcus; newborn; neonatal encephalopathy; hypoxic-ischemic encephalopathy; therapeutic 
hypothermia. 
Intrapartum complications with hypoxic brain injury is one of 
the leading causes of neonatal mortality and long-term impair-
ment morbidity worldwide [1]. Newborns exposed to a perina-
tal insult typically present with neonatal encephalopathy (NE), 
a descriptive term for a clinical constellation of neurological 
dysfunctions in the term infant [2]. Many cases of NE, and the 
often-resultant neonatal death or stillbirth, are likely to result 
from a complex multifactorial pathway to brain injury to which 
hypoxia-ischemia substantially contributes [3–6].
Hypoxic-ischemic encephalopathy (HIE) is a term used 
to define those cases with NE likely due to hypoxia-ischemia. 
Across many high-income countries (HICs), it is now standard 
of care for infants with moderate to severe HIE to be treated 
with whole-body therapeutic hypothermia or “cooling,” where 
their core body temperature is cooled to 33.5°C for 72 hours, 
followed by a controlled period of rewarming [7, 8]. Systematic 
reviews of cooling trials have shown that therapeutic hypother-
mia is able to reduce the combined outcome of death or major 
neurodevelopmental disability in survivors, with a number 
needed to treat  =  7 for an additional beneficial outcome [9]. 
To define which infants should receive cooling, clinical crite-
ria have been developed to identify NE assumed to be due to 
hypoxia-ischemia. The presence of other comorbidities such as 
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acute perinatal infection, however, does not usually preclude 
cooling treatment. A systematic review of cooling in low- and 
middle-income countries (LMICs) failed to show a statistically 
significant reduction in neonatal mortality [10]; however, indi-
vidual centers in middle-income settings have reported favora-
ble outcomes [11].
Increasing evidence suggests the importance of a sensitiz-
ing effect of inflammation, increasing the susceptibility of the 
immature brain to perinatal events that drive the pathogene-
sis of NE [12, 13]. Animal studies have shown that exposure 
to bacterial endotoxin increases vulnerability of the develop-
ing brain to hypoxia-ischemia [14–16]. Other study findings 
have shown a temporal relationship suggesting that exposures 
can be sensitizing or preconditioning to the fetal and neona-
tal brain [13, 15, 16]. A recent study, modeling gram-positive 
infection prior to hypoxic-ischemic injury, demonstrated sen-
sitization of the brain to injury, but also encouragingly, neuro-
protection with hypothermia [17]. In clinical studies, factors 
associated with intrauterine infection and inflammation, 
such as prolonged rupture of membranes, have been shown 
to be associated with NE [5], and the presence of placental 
inflammation/infection has been shown to be independently 
associated with an increased risk of NE in both high- and 
low-income settings [18, 19]. While few clinical studies have 
examined the role of specific infections and inflammation as 
independent risk factors for NE, an important role is hypoth-
esized [20, 21].
Group B Streptococcus (GBS; Streptococcus agalactiae) is an 
important pathogen for newborns and is one of the most common 
causes of neonatal infection worldwide [22]. Defining the contribu-
tion of GBS to other important and common neonatal conditions, 
such as NE, is important to fully understand the global burden of 
GBS in pregnant women and infants, and because it may become 
potentially preventable, through maternal GBS vaccination.
This article aims to examine the proportion with GBS disease 
among infants with NE (Figure 1).
Objectives
1. To undertake to provide a comprehensive and systematic 
literature review and identify unpublished cohorts through 
an investigator group formed through trials and registries of 
infants with NE assumed to be due to hypoxia-ischemia meet-
ing criteria for therapeutic hypothermia, in order to analyze 
the risk of invasive GBS disease among neonates with NE.
2. To assess the data available for the proportion with invasive 
GBS disease among infants with NE in order to estimate the 
burden of GBS in pregnant women, stillbirths, and infants.
3. To evaluate data gaps and recommend improvements for 
data acquisition on NE associated with GBS disease.
Figure 1. Neonatal encephalopathy (NE) is part of the compartmental model to estimate the burden of group B streptococcal (GBS) disease, as described by Lawn et al [54].
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METHODS
This article is part of a protocol entitled “Systematic estimates 
of the global burden of GBS in pregnant women, stillbirths and 
infants,” submitted for ethical approval to the London School 
of Hygiene & Tropical Medicine (reference number 11966) and 
approved on 30 November 2016.
Definitions
Case definitions used in this article include NE, HIE, intra-
partum-related death, and birth asphyxia; these are shown in 
Supplementary Table 1, in addition to definitions of GBS sep-
sis, meningitis, and pneumonia. For the study of the association 
between GBS and NE, a case of GBS was defined as isolation of 
GBS, on either blood culture or molecular assay, from a nor-
mally sterile site (blood, cerebrospinal fluid, postmortem site).
DATA SEARCHES AND INPUTS
Published Data
We conducted systematic literature searches of Medline and 
Embase on 28 September 2016, and Literature in the Health 
Sciences in Latin America and the Caribbean (LILACS), 
the World Health Organization Library Information System 
(WHOLIS), and Scopus on 12 February 2017, and updated 
these on 21 March 2017. We searched with variants of terms 
related to “GBS,” “sepsis,” “asphyxia,” therapeutic hypothermia,” 
and “NE” (Supplementary Materials). Medical subject head-
ing (MeSH) terms were used where possible. Supplementary 
Table 2 describes the full list of search terms. One investigator 
performed the database search, and screened for duplicates 
and for eligibility (M. V.). Two independent investigators (M. 
V. and N. R.) screened abstracts to assess their suitability for 
inclusion, and both reviewers subsequently extracted data. 
Where there was discrepancy between the 2 reviewers, a third 
investigator (C. T.) made the final decision. Additional articles 
were identified from reference lists through snowball search-
ing. We did not apply date or language restrictions and texts 
were translated to English when published in other languages.
Secondary Analysis of Data From Published Neonatal Encephalopathy 
Cohorts and Trials From the Investigator Group
Through snowball searching of reference lists, and a search on 
PubMed using terms related to infant/newborn/NE and ther-
apeutic hypothermia (S.S.), cooling cohorts and trials were 
identified. As these articles did not include data related to GBS, 
the corresponding authors were contacted on a minimum of 2 
occasions (at least 4 weeks apart) to inquire whether data on the 
proportion of GBS disease among infants with NE/HIE were 
available for secondary analysis. A consistent definition of GBS 
disease was used (Supplementary Table 1). Responding authors 
were requested to complete a standardized data collection 
spreadsheet summarizing the data.
Unpublished Data From the Investigator Group
Unpublished data from patient registers in HICs were sourced 
from registers of therapeutic hypothermia (“cooling” registers), 
patient registers from neonatal neurology centers, and national 
neonatal research databases.
Neonatal neurology and cooling cohorts and registers were 
identified through literature review as above and through pro-
fessional networking. Lead clinicians at the relevant sites were 
contacted and requested to complete the same standardized 
data collection spreadsheet summarizing the data to those pro-
viding data for secondary analysis above.
Centers known to be holding national neonatal data (United 
Kingdom, Canada, Australia, Norway) were contacted and 
invited to contribute data. Of these, the United Kingdom 
National Neonatal Research Database (NNRD) and the 
Canadian Neonatal Network (CNN) agreed to contribute data. 
The NNRD holds electronic patient record data, recorded by 
health professionals as part of routine clinical care, from United 
Kingdom neonatal units. Data held in the NNRD are cleaned; 
records with implausible data configurations are queried and 
corrected by the treating clinicians. The NNRD holds individual 
patient-level data from all admissions to National Health Service 
(NHS) neonatal units in England and Wales from 2012 and from 
all admissions to Scottish neonatal units from 2014. A formal 
comparison of NNRD data items against those recorded in case 
record forms of a multicenter, randomized placebo-controlled 
trial (Probiotics in Preterms [23]) demonstrated a high degree 
of data agreement (>95%) between the NNRD and clinical trial 
case report forms. The National Neonatal Research Database 
is a Clinical Dataset (National Neonatal Data Set) within the 
NHS Data Dictionary. Details of all data items are searcha-
ble at the following webpage: http://www.datadictionary.nhs.
uk/data_dictionary/messages/clinical_data_sets/data_sets/
national_neonatal_data_set/national_neonatal_data_set_-_
episodic_and_daily_care_fr.asp?shownav=1.
For the purposes of this study, NE meeting the criteria for 
therapeutic hypothermia was defined as an infant >35 weeks’ 
gestation receiving at least 2 days of therapeutic hypothermia. 
The data were limited to infants receiving a minimum of 2 days’ 
therapeutic hypothermia to ensure exclusion of babies initially 
cooled but then rewarmed within a few hours after transfer to 
their tertiary cooling center and not found to adequately meet 
cooling criteria.
Data from Canada were extracted from the CNN database. 
The CNN holds abstracted data from patient charts by trained 
abstractors after discharge of patient from the neonatal inten-
sive care unit (NICU) according to manual definitions. Data are 
cleaned at the coordinating center in Toronto and records with 
implausible data configurations are queried and corrected. The 
CNN holds individual patient-level data from all admissions to 
participating neonatal units in Canada from 1996. Since 2010, 
25 of 28 NICUs in the country participated in data collection 
S176 • CID 2017:65 (Suppl 2) • Tann et al
and, since 2012, all 30 units representing 100% coverage of 
those admitted to NICU in Canada. A  formal reabstraction 
comparison has revealed it to be reliably reproducible. For 
the purposes of this study, infants with NE meeting National 
Institute for Child Health and Human Development (NICHD) 
cooling criteria were included. GBS disease was identified as 
GBS isolated from a sterile site (ie, blood, cerebrospinal fluid, 
or both).
ESTIMATING THE UK INCIDENCE OF GROUP 
B STREPTOCOCCUS-ASSOCIATED NEONATAL 
ENCEPHALOPATHY
The number of term infants receiving ≥2 days cooling with GBS 
disease in England, Scotland, and Wales was identified from 
the NNRD database. Denominator data on term live births in 
England and Wales from 2012 to 2015 were identified from the 
UK Office for National Statistics [24]; and term live births in 
Scotland from 2014 to 2015 were identified from the National 
Records of Scotland [25]. These data were used to calculate the 
UK incidence of GBS-associated NE.
Inclusion and Exclusion Criteria
For both published and unpublished data, we only considered 
original data including a denominator of at least 50 and we did 
not apply date or language restrictions (Supplementary Table 3). 
We included published and unpublished data for infants >35 
weeks’ gestation with neonatal or HIE reporting on invasive 
GBS disease in the first 90 days after birth. Studies with nonrep-
resentative samples of cases and unsuitable article types such as 
case reports were excluded.
Meta-analyses
Data on study characteristics and results were extracted into 
standardized prespecified Excel abstraction forms, and then 
imported to Stata 14 software (StataCorp) for meta-analyses. 
We used random-effects meta-analyses to estimate the propor-
tion of infants with NE with GBS disease using the DerSimonian 
and Laird method [26]. Only datasets reporting the proportion 
of infants with GBS disease among those with NE assumed to 
be as a result of hypoxia-ischemia meeting the criteria for ther-
apeutic hypothermia were included in the meta-analysis as this 
provided the most robust comparable denominator. Data from 
individual centers in the United Kingdom and Canada were not 
included in the meta-analysis due to overlap with the included 
national-level data. We conducted subgroup analysis for ante-
natal GBS screening practices.
Death to Discharge and Longer-term Outcomes
Case fatality rates up until discharge among NE infants with 
and those without GBS disease were collected where avail-
able. Long-term outcome data, including mortality, cere-
bral palsy, and neurodevelopmental follow-up scores were 
sought. To estimate the difference between predischarge 
mortality for NE infants with and without GBS, we used a 
Mantel-Haenszel random-effects meta-analysis (RevMan 
5.3) to generate the risk ratio (RR) and a z test to determine 
significance [27].
RESULTS
Literature and Investigator Group Data Inputs
We identified 10 804 studies through database searches. Of 
these, 137 full texts were reviewed and 4 studies met the inclu-
sion criteria (Figure 2). Through the investigator group, an add-
itional 13 were obtained from secondary analysis of published 
data, 10 from local cooling or neonatal neurology cohorts and 2 
from national neonatal network research databases (Figure 2). 
Overall, 29 datasets met inclusion criteria; of these, 17 were eli-
gible for inclusion in the meta-analysis. A total of 10 436 infants 
were included; this number does not include datasets that either 
overlap with the United Kingdom or Canada national data, or 
the secondary analysis data from Jenster et al [20], which over-
lapped with the unpublished US cooling cohort dataset pro-
vided by H.C. Glass.
Study Characteristics
Characteristics of published studies and unpublished data-
sets from our investigator group are shown in Table  1. 
Contributed data came from 13 countries (Figure  3). Only 
4 published studies included data on GBS disease among 
infants with NE [19, 20, 28, 29]. Published and unpublished 
data were reported from both developed and developing 
countries (Figure 3); the majority are from HICs, in particu-
lar the United Kingdom, United States, and Canada. Of the 
4 eligible published studies, 2 (1 US and 1 United Kingdom 
study) reported on blood culture results among a cohort of 
encephalopathic infants from the precooling era [20, 30]. 
A further published study from Turkey included culture data 
from infants meeting criteria for cooling among a cohort of 
encephalopathic infants [28]. The final published study was 
from a low-income setting, Uganda [19, 29]; the only cases 
(3) detected were detected with high cycle threshold values 
on species-specific real-time polymerase chain reaction [19]. 
National-level data were reported from 2 developed countries 
(United Kingdom and Canada). Secondary analyses of micro-
biological data were available from 4 cooling trials (CoolCap, 
TOBY Xenon, NICHD, and the Infant Cooling Evaluation 
Collaboration [ICE] trial [31–34]) and 9 encephalopathy 
cohorts [5, 6, 18, 29, 30, 35–38]. Unpublished datasets from 
our investigator group (10), reporting GBS disease among 
infants meeting criteria for cooling, were provided from 9 
cooling registers from the United Kingdom, United States, 
Canada, Australia, and the Netherlands, with 2 further data-
sets for infants with NE who did not meet cooling criteria 
from Spain and Canada.
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Therapeutic whole-body cooling became standard of care 
across many high-income-country settings from 2008 to 2009, 
meaning the majority of datasets included here are from 2008 
onward. Commonly used criteria for therapeutic hypother-
mia are summarized in Supplementary Table 4. However, 
cooling trial data from as early as 1999 are also included from 
the CoolCap Trial [31]. Data are reported from settings with 
a variety of approaches to intrapartum antibiotic prophylaxis 
(IAP) for maternal GBS colonization including areas with 
active screening (eg, United States, Canada, Australia) to those 
using a risk factor–based approach (eg, the Netherlands, United 
Kingdom, and Ireland) and those with no defined national 
approach to IAP for early-onset GBS prevention (eg, Uganda, 
India, and Nepal). All data reported on infants born at >35 
weeks completed gestational age and includes a wide range of 
birth weights (Table 1).
Proportion of Group B Streptococcus Disease Among Infants With 
Neonatal Encephalopathy
Twenty-one studies reported on the proportion of GBS dis-
ease among infants with NE, assumed to be due to hypoxia-is-
chemia, meeting criteria for cooling (Table 2). An additional 
8 studies reported on the proportion of GBS disease among 
infants with NE not meeting cooling criteria (Table  3). The 
Figure 2. Search strategy and process of study selection regarding group B streptococcal disease among cases of neonatal encephalopathy. Abbreviations: GBS, group B 
Streptococcus; HIE, hypoxic-ischemic encephalopathy; NE, neonatal encephalopathy.
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proportion with GBS disease among all cohorts varied from 
0 to 2.4%. The highest rates of GBS-associated NE were 
reported in cohorts from the United Kingdom, United States 
[34], Ireland [18], Canada, and Malaysia where the proportion 
with GBS disease in all was >1%. Cohorts from the United 
States [20], Australia, Spain [36], Turkey [28], India [29], and 
Table 2. Proportion of Group B Streptococcus Among Cases With Neonatal Encephalopathy Assumed to Be Due to Hypoxia-Ischemia Meeting Criteria 
for Therapeutic Hypothermia
Country Location Year(s) Author Database Denominatora
NE 
Cases
GBS 
Invasive 
Disease
% of 
NE With 
GBS
 Developed
 UK National 2009–2016 NDAU National research 
database
HIE, cooling criteria 6041 72 1.19
 Canada National 2010–2015 CNN National research 
database
HIE, cooling criteria 1184 2 0.17
 International, multisite CoolCap trial 1999–2003 Gunn, A Cooling trial HIE, cooling criteria 234 1 0.43
 US, multisite NICHD cooling trial 2000–2003 Shankaran, S Cooling trial HIE, cooling criteria 208 5 2.40
 International, multisite ICE Trial 2001–2007 Jacobs, SE Cooling trial HIE, cooling criteria 221 3 1.36
 UK, multisite TOBY Xenon trial 2012–2014 Edwards, AD Cooling trial HIE, cooling criteria 92a 2 2.17
 US Maryland 2007–2015 Johnson, CT Cooling cohort HIE, cooling criteria 57 1 1.75
 Spain Barcelona 2009–2011 Garcia-Alix, A Cooling cohort HIE, cooling criteria 53 0 0
 Ireland Dublin 2010–2015 Hayes, B Cooling cohort HIE, cooling criteria 76 1 1.31
 UK Bristol 2007–2016 Thoresen, M Cooling register HIE, cooling criteria 292a 2 0.68
 US San Francisco 2008–2015 Glass, HC Cooling register HIE, cooling criteria 252 0 0
 The Netherlands Utrecht 2008–2010 Groenendaal, F Cooling register HIE, cooling criteria 192 4 2.08
 US Boston 2008–2017 Walsh, BH Cooling register HIE, cooling criteria 72 0 0
 US Washington, DC 2008–2016 Massaro, AN Cooling register HIE, cooling criteria 187 2 1.07
 Canada Montreal 2009–2016 Wintermark, P Cooling register HIE, cooling criteria 253a 3 1.18
 UK London 2010–2016 Tann, CJ 
Robertson, NJ
Cooling register HIE, cooling criteria 256a 6 2.34
 Australia Melbourne 2010–2016 Cheong, J Cooling register HIE, cooling criteria 128 0 0
 Spain Barcelona 2010–2016 Arca-Diaz, G Cooling register HIE, cooling criteria 90 0 0
 Asia
 Turkey Ankara 2011–2013 Okomus, N Cooling cohort HIE, cooling criteria 74 0 0
 Malaysia Multisite 2012 Boo, NY Cooling cohort HIE, cooling criteria 919 10 1.09
Africa
 South Africa Cape Town 2008–2011 Kali, G Cooling cohort HIE, cooling criteria 94 1 1.06
Abbreviations: CNN, Canadian Neonatal Network; GBS, group B Streptococcus; HIE, hypoxic-ischemic encephalopathy; ICE, Infant Cooling Evaluation Collaboration; NDAU, Neonatal Data 
Analysis Unit; NE, neonatal encephalopathy; NICHD, National Institute of Child Health and Human Development; TOBY, Total Body Hypothermia; UK, United Kingdom; US, United States.
aCases not included in the total denominator, where there is overlap with national data or another dataset.
Figure 3. Geographic distribution of data inputs on neonatal encephalopathy with data on group B streptococcal disease. Borders of countries/territories in map do not 
imply any political statement. 
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Nepal [6] reported no GBS disease among infants with NE. 
However, of the 10 datasets with 0 GBS cases, the number of 
births were 53, 54, 72, 74, 89, 90, 95 128, 252, and 258, so the 
only 2 datasets powered to detect this low expected propor-
tion were those from the same US center with a known high 
coverage of IAP [20].
Meta-analysis of the Proportion of Group B Streptococcus Disease Among 
Infants Meeting Criteria for Therapeutic Hypothermia
Seventeen datasets were eligible for inclusion in the meta-anal-
ysis examining the proportion of GBS disease among infants 
with encephalopathy meeting criteria for therapeutic hypother-
mia (Figure 4). Three UK datasets and 4 Canadian datasets were 
Table 3. Proportion of Group B Streptococcal Disease Among Cases of Neonatal Encephalopathy
Country Location Year Author Database Denominator Cases
GBS Invasive 
Disease
% of NE With 
GBS
 Developed
 UK/ 
Netherlands
London/ Utrecht 1992–1998 Cowan, F 
de Vries, LS
Published NE, not meeting cooling 
criteria
253b 2 0.79
 UK London 1992–2007 Martinez-Biarge, M
Cowan, F
Published NE, not meeting cooling 
criteria
259b 5 1.93
 US San Francisco 1993–2011 Jenster, Ma Published NE, clinical criteria 258b 0 0
 Canada Montreal 2009–2016 Wintermark, P Neonatal neurology 
register
NE, not meeting cooling 
criteria
249b 1 0.40
 Asia
 India Kerala 2009 Thayyil, S Cooling cohort NE, clinical criteria 54 0 0
 Nepal Kathmandu 1995–1996 Ellis, M Observational study data NE, clinical criteria 95 0 0
 India Multisite 2013–2015 Thayyil, S Observational study data NE, clinical criteria 89 0 0
 Africa
 Uganda Kampala 2011–2012 Tann, CJ Case-control study NE, clinical criteria 210 3 1.43
Abbreviations: GBS, group B Streptococcus; NE, neonatal encephalopathy; UK, United Kingdom; US, United States.
aThe only baby reported to be GBS positive was found to be group A Streptococcus positive; erratum awaiting publication.
bNumber of cases not included in the total denominator, where there is overlap with national data or another dataset.
Figure 4. Meta-analysis of the proportion of group B Streptococcus identified from a sterile site among infants with neonatal encephalopathy assumed to be due to hypox-
ic-ischemic encephalopathy, in infants meeting criteria for therapeutic hypothermia. Abbreviations: CI, confidence interval; CNN, Canadian Neonatal Network; ES, estimate; 
GBS, group B Streptococcus; NDAU, Neonatal Data Analysis Unit.
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excluded from the meta-analysis because the data overlapped 
with the included national neonatal data from the same coun-
tries. Data inputs were all from HICs in the UN “developed” 
region, with the exception of Malaysia and South Africa, both 
upper-middle–income countries. No studies from low-income 
countries (LICs) were eligible for inclusion in the meta-analy-
sis as diagnostic techniques required for cooling criteria such 
as cord and blood gas estimation and cerebral function mon-
itoring are largely unavailable. Among those included in the 
meta-analysis, the proportion with GBS disease among infants 
with NE meeting cooling criteria was 0.58% (95% confidence 
interval [CI], .18%–.98%; range, 0–2.40%) (Figure 4). Subgroup 
analysis by antenatal screening practice demonstrated a propor-
tion with GBS disease of 1.09 (95% CI, .84–1.35) for datasets 
without an antenatal GBS screening policy, compared with 0.21 
(95% CI, .00–.48) for datasets where antenatal screening was 
routine (Supplementary Figure 1). One dataset (CoolCap) was 
excluded from this subgroup analysis due to varying screening 
practices across multiple sites.
Death to Discharge and Longer-Term Outcomes
Studies reporting on case fatality among infants with NE, with 
and without GBS disease, are presented in Table 4. Case fatality 
to discharge among infants with NE was reported in 24 stud-
ies: 2 from national research data (United Kingdom, Canada), 
3 from secondary analysis of cooling trial data (CoolCap [31], 
NICHD [34], and ICE [33]), and 19 from NE cohorts. However, 
of these, 8 studies reported no GBS disease in their NE cohort, 
and 4 overlapped with national data. The remaining 12 data-
sets were used to compare the case fatality in GBS-associated 
NE and NE alone. Case fatality before discharge for these 12 
datasets combined was 1305 of 9525 (13.7%) infants with NE 
alone compared with 22 of 105 (21%) infants with NE and GBS 
(P < .0001). Risk of mortality before discharge was significantly 
increased in those infants with GBS-associated NE compared 
to those without GBS disease (risk ratio [RR], 2.07 [95% CI, 
1.47–2.91]; Supplementary Figure  2). A  sensitivity analysis, 
excluding cohorts with the lowest GBS incidence, did not mark-
edly alter this RR. Longer-term outcome data were consistently 
Table 4. Case Fatality at Discharge Among Infants With Neonatal Encephalopathy With and Without Group B Streptococcal Disease
Country Location Author Denominator
Case Fatality Among Infants With NE, no./No. (%)
Overall With Invasive GBS No Invasive GBS 
Developed
 UK NNRD NDAU HIE, cooling criteria 638/6041 (10.6) 9/72 (12.5) 629/5969 (10.5)
 Canada National CNN HIE, cooling criteria 211/2250 (9.3) 3/4 (75.0) 208/2246 (9.3)
 International Multisite Gunn, A HIE, cooling criteria 58/234 (24.8) 1/1 (100.0) 57/233 (24.5)
 US Multisite Shankaran, S HIE, cooling criteria 62/208 (29.8) 2/5 (40) 60/203 (29.6)
 International Multisite Jacobs, SE HIE, cooling criteria 58/221 (26.2) 1/3 (33.3) 57/218 ((26.1)
 US Maryland Johnson, CT HIE, cooling criteria 3/57 (5.26) 0/1 (0) 3/56 (5.36)
 Spain Barcelona Garcia-Alix, A HIE, cooling criteria 16/51 (31.4) 0/0 (0) 16/51 (31.4)
 Ireland Dublin Hayes, B HIE, cooling criteria 17/76 (22.4) 1/1 (100) 16/75 (21.3)
 US California Glass, HC HIE, cooling criteria 26/252 (10.32) 0/0 (0) 26/252 (10.32)
 The Netherlands Utrecht Groenendaal, F HIE, cooling criteria 63/192 (32.8) 0/4 (0) 63/192 (32.8)
 US Boston Walsh, BH HIE, cooling criteria 3/72 (4.2) 0/0 (0) 3/72 (4.2)
 US Washington, DC Massaro, AN HIE, cooling criteria 30/187 (16.0) 1/2 (50.0) 29/185 (15.7)
 Canada Montreal Wintermark, P HIE, cooling criteria 36/253 (14.2) 0/4 (0) 36/249 (14.5)
 UK London Tann, CJ
Robertson, N
HIE, cooling criteria 30/187 (16.0) 1/2 (50.0) 29/185 (14.7)
 Australia Melbourne Cheong, J HIE, cooling criteria 34/128 (26.5) 0/0 (0) 34/128 (26.5)
 Spain Barcelona Arca-Diaz, G HIE, cooling criteria 8/90 (8.89) 0/0 (0) 8/90 (8.89)
 UK London Martinez-Biarge, M
Cowan, F
NE, clinical criteria 22/259 (8.50) 0/5 (0) 22/259 (8.50)
 Canada Montreal Wintermark, P NE, clinical criteria 6/249 (2.4) 0/1 (0) 6/248 (2.4)
 Asia
 Malaysia Multisite Boo, N-Y HIE, cooling criteria 144/919 (15.6) 4/10 (40.0) 140/909 (15.4)
 Nepal Kathmandu Ellis, M NE, clinical criteria 40/142 (28.2) 0/0 (0) 40/142 (28.2)
 India Kerala, Thayyil, S NE, clinical criteria 6/54 (11.1) 0/0 (0) 6/54 (11.1)
 India Multisite Thayyil, S NE, clinical criteria 16/89 (18.0) 0/0 (0) 16/89 (18.0)
 Africa
 South Africa Cape Town Kali, G HIE, cooling criteria 14/99 (14.1) 0/1 (0) 14/98 (14.3)
 Uganda Kampala Tann, CJ NE, clinical criteria 70/208 (33.7) 2/3 (66.6) 68/205 (33.2)
Abbreviations: CNN, Canadian Neonatal Network; GBS, group B Streptococcus; HIE, hypoxic-ischemic encephalopathy; NDAU, Neonatal Data Analysis Unit; NE, neonatal encephalopathy; 
NNRD, UK National Neonatal Research Database; UK, United Kingdom; US, United States.
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reported as either incomplete or not available and so are not 
reported here.
UK Population-Level Data
The number of infants with GBS-associated NE in England 
and Wales between 2012 and 2015 was 55 and the number of 
term live births identified over the same period in England 
and Wales, according to the Office for National Statistics, was 
2 821 271 [24]. The number of infants with GBS-associated NE 
in Scotland between 2014 and 2015 was 1 and the number of 
term live births identified over the same period in Scotland was 
111 823 [25]. Northern Ireland population-level NE data were 
not available. The UK incidence of GBS-associated NE was 
therefore 0.019 (95% CI, .019–.02) per 1000 live births.
DISCUSSION
This systematic review and meta-analysis is the first to esti-
mate the percentage of GBS disease in neonates with NE and to 
assess differences in survival outcomes compared with infants 
with NE alone. Overall published data are lacking; however, by 
including national research databases, secondary analyses, and 
data from neonatal neurology registers we have been able to 
include comparable data from 29 centers, across 13 countries. 
The contribution from a large number of investigator groups 
across the globe has provided an extensive dataset for this paper 
addressing GBS disease with NE. Due to the sizeable dataset 
denominator, we are able to more accurately determine the pro-
portion of NE associated with GBS, and estimate differences 
in mortality outcome. Our findings show that infants with NE 
are >10 times more likely to be affected by invasive GBS dis-
ease than term infants without NE. The national UK data also 
enabled the first population-wide incidence estimate of GBS-
associated NE, which has contributed to our understanding of 
the global burden of GBS disease [39].
The contribution of the UK NNRD and Canadian CNN 
national data have enabled inclusion of every infant admitted 
to the NICU with NE fulfilling criteria for therapeutic hypo-
thermia in these 2 countries. In addition, the systematic review, 
performed to identify published data on GBS-associated NE, is 
comprehensive, reproducible, and was conducted on multiple 
databases, without limitation by language. A  range of search 
terms to describe NE were utilized to allow for shifting termi-
nology and definitions. Our findings show that 0.58% (95% CI, 
.18%–.98%) of infants with NE who meet criteria for therapeu-
tic hypothermia have GBS disease. This is >10-fold higher than 
the 0.046% (95% CI, .038%–.053%) developed region estimate 
of GBS disease for all term liveborn infants [40].
The incidence of GBS-associated NE ranged from 0% to 2.4%, 
without restriction to those achieving cooling criteria. There was 
notable disparity between the 2 largest datasets—the UK and 
Canada national research databases had 1.19% and 0.17% GBS 
disease, respectively. The variation is possibly a reflection of the 
low overall incidence of identified GBS-associated NE; however, it 
is important to consider the role of intrapartum GBS prophylaxis. 
Our meta-analysis included data from countries that routinely 
screen and treat for maternal GBS colonization (United States, 
Canada, Australia), countries that take a risk factor approach to 
screening (UK, Ireland, Malaysia, Spain, South Africa) and coun-
tries with no current policy (Turkey). GBS disease was more fre-
quently found in NE infants receiving cooling in countries that do 
not routinely screen mothers (proportion with GBS, 1.09% [95% 
CI, .84%–1.35%]) compared to other countries that do (propor-
tion with GBS, 0.21% [95% CI, .00%–.48%]). It is notable that a 
number of NE cohorts from India and Nepal, with no reported 
policy for GBS prophylaxis, had no infants with GBS-associated 
NE. It is unclear why these cohorts have zero case ascertainment, 
although early death in settings where neonatal intensive care is 
not available may have contributed. The US NICHD dataset has 
the largest incidence of GBS (2.4%) [34] and is an outlier among 
others in the subgroup with antenatal GBS screening.
Meta-analysis of the proportion of GBS identified from 
a sterile site among infants with NE is only a measure of the 
proportion of NE with GBS disease. From a public health per-
spective, to obtain a population incidence of GBS-associated 
NE also necessitates data regarding the incidence of NE per 
1000 live births. UK national data [24, 25] can provide popu-
lation-wide estimates of GBS associated NE. We estimate that 
GBS-associated NE occurs in 0.019 per 1000 overall live births 
(95% CI, .019–.02 per 1000 live births).
The risk of death before discharge was doubled for infants 
with a combination of NE and GBS disease, compared with NE 
alone (GBS-associated NE mortality was 21% compared with 
13.7% for NE alone; RR, 2.07 [95% CI, 1.47–2.91]; P < .0001). 
This must be interpreted cautiously in view of the small denom-
inator size among the GBS-associated NE group. The increased 
deaths may have been due to overwhelming sepsis; however, it 
is also biologically plausible that sensitization by inflammation 
increased the extent of brain injury relative to the severity of 
an ischemic insult alone, as demonstrated in preclinical mod-
els [14, 41]. Systemic illness for infants affected with infection 
and hypoxia-ischemia is likely to be more severe, with a com-
bination of hypoxic injury and inflammatory cascade–induced 
dysfunction of organ systems. In one clinical HIE cohort of 258 
infants, evidence of neonatal sepsis was associated with a sig-
nificant increase in brain injury on neuroimaging and a trend 
toward increased mortality and neurodevelopmental impair-
ment [20]. Importantly, in inflammation-sensitized HIE pre-
clinical models, hypothermia has been shown to be variably 
neuroprotective [17, 42]. A recent study, modeling gram-pos-
itive infection prior to HI injury, demonstrated sensitization of 
the brain to HI injury, but also encouragingly, neuroprotection 
with hypothermia [40]. Therapeutic hypothermia may also con-
tribute to systemic instability in sepsis (eg, independently low-
ers blood pressure) [43]. Additionally, therapeutic hypothermia 
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causes chemokine-associated immunosuppression, which 
reduces peripheral leukocyte numbers [44] and may impair 
immune responsiveness to GBS. Reassuringly, treatment with 
therapeutic hypothermia was not associated with an increase 
in culture-positive sepsis in a large meta-analysis of therapeutic 
hypothermia efficacy [9]. The possible higher risk of mortality 
with GBS-associated NE, and the difficulties in differentiating 
sepsis, highlights the importance of empiric antibiotics for all 
infants with NE while investigations for concomitant infection 
are ongoing or where infection cannot easily be ruled out.
Paucity of Data Especially in Low- and Middle-Income Countries
There were no published data specific to GBS-associated NE, 
and only 4 published studies reporting on GBS incidence in 
NE cohorts. This lack of data was overcome, in part, through 
the participation of the many contributions through our 
investigator group.
NE is estimated to be the cause in 23% of neonatal deaths 
worldwide, with 99% of all neonatal deaths occurring in 
LMICs [45]. The incidence of intrapartum-related NE has 
been estimated to be 14.9 per 1000 live births in LMICs com-
pared to 1.6 per 1000 live births in HICs [2], with 95% of 
global death and impairment secondary to intrapartum-re-
lated events occurring in LMICs [2]. The meta-analysis of 
GBS-associated NE among infants does not include any data 
from LICs, where therapeutic hypothermia is not in wide-
spread use, and any published data were from prohibitively 
small cohorts. It can be postulated, however, that the burden 
of GBS disease in combination with NE is likely to be greater 
in LIC settings and our estimates of the incidence of GBS-
associated NE are likely to be an underrepresentation of the 
global problem.
Paucity of Data for Long-Term Impairment
Death before discharge was the only available outcome meas-
ure examined. Ideally, short-term outcomes that have been 
found to be predictive of longer-term outcomes, such as mag-
netic resonance imaging (MRI), would also be reported. More 
importantly, there were insufficient follow-up data available 
to determine long-term outcome, and these data are generally 
lacking after NE [2], after neonatal infections [22], and nota-
bly after GBS [46]—from which this group of infants with 
GBS-associated NE can be considered distinct. Investigator 
groups reported a lack of consistent follow-up of these infants 
as the reason for the paucity of data. If, as preclinical studies 
suggest, there is increased neuronal injury in newborns with 
inflammation-sensitized HIE, the risk of neurodevelopmental 
impairment and later mortality is likely to be increased. In 1 
case-control study, cerebral palsy was strongly associated with a 
combination of clinical chorioamnionitis and MRI evidence of 
hypoxic-ischemic injury (odds ratio, 17.5 [95% CI, 3.3–93.4]; 
P = .001) [47].
Paucity of Data in Stillbirths
Stillborn infants are an important group of infants not repre-
sented in our analysis. Recent analyses show the important con-
tribution of infections to the global toll of 2.6 million annual 
stillbirths [48], but data on GBS and stillbirth are limited [49]. 
Combined hypoxia-ischemia and GBS disease during labor 
may result in even more intrapartum stillbirths than neonatal 
deaths as preclinical models demonstrate an inability by inflam-
mation-sensitized newborns to survive a hypoxic-ischemic 
insult [41, 42].
Neonatal Encephalopathy Case Definition and Subsequent Bias
NE is a descriptive term for a constellation of clinical features, 
without ascribing cause [50]. Terms such as birth asphyxia, 
perinatal asphyxia, HIE, and NE are often interchangeably 
and incorrectly used [2]. To address this in the meta-analysis, 
and ensure the denominator was comparable between cohorts, 
evidence of fulfilling the relatively comparable criteria for 
therapeutic hypothermia was used. However, the criteria for 
cooling were designed to specifically identify that subgroup of 
infants with NE where hypoxia-ischemia is assumed to be the 
primary etiology. However, as a result of this, infants with NE 
due to causes other than intrapartum asphyxia will be under-
represented in our analysis. Septic infants presenting with 
NE (abnormal neurological symptoms are present in 63% of 
neonates with GBS disease [51]) will not be included in the 
meta-analysis unless they also had evidence of intrapartum 
asphyxia. Additionally, infants with overwhelming sepsis may 
be excluded from cooling even in the presence of HIE.
For the UK NNRD dataset, only infants cooled for ≥2 days 
were included in analysis. This was to ensure exclusion of infants 
without clinical evidence of moderate to severe HIE, who were 
subsequently rewarmed early. As a result, cases will be missed, 
namely, those that died on the first day or were rewarmed early 
due to severity of systemic illness.
Cohorts with NE cases not specifying fulfilment of cool-
ing criteria were excluded from meta-analysis; however, this 
excluded data from LICs. This selection bias to our estimate is 
likely to underrepresent the true incidence of GBS-associated 
NE since the incidence of NE has been reported to be 10 times 
higher in low-resource settings [2], and infectious comorbidity 
is also likely to be higher.
Group B Streptococcus Case Ascertainment
Diagnosing GBS invasive disease is an important challenge, as 
outlined in elsewhere in this supplement [52]. The yield of cul-
tures is recognized to be low in neonates due to prior receipt 
of intrapartum antibiotics; small specimen volume; and prior-
itization of rapid administration of postnatal antibiotics over 
sampling, especially for lumbar punctures. “Culture-negative” 
sepsis is a well-recognized entity in neonatal medicine [53]. 
Polymerase chain reaction testing for GBS is available but not 
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widely adopted yet. GBS isolated from the skin, mucosa, tra-
chea, or urine was not included in this review due to the uncer-
tainty over colonization vs infection. The number of cases of 
GBS invasive disease is therefore likely underrepresented.
Improving the Data
The paucity of data on concomitant infection in NE, and long-
term outcomes for infants with NE needs to be addressed. It 
is notable that most major cooling collaboratives reported that 
they do not routinely collect data or report on GBS or other 
coinfection; given the likely contributory role and increase in 
mortality, we recommend this be implemented for GBS and for 
other peripartum pathogens such as gram-negative organisms. 
Future trials of neuroprotective adjuncts to therapeutic hypo-
thermia should incorporate data collection relevant to intrapar-
tum and neonatal infection, and consider secondary analysis 
split by presence of infection. Importantly, long-term neurode-
velopmental follow-up of all NE infants should be standard 
practice, both for clinical care and for quality improvement 
purposes. Addressing data gaps in LMICs should be prioritized.
Public Health Implications
Our conservative estimate of GBS disease occurring in only 
0.58% of NE cases has a larger impact when applied on a global 
scale. Worldwide there are an estimated 1.16 million cases of 
NE per year (8.5 per 1000 live births), resulting in a quarter 
of neonatal deaths [45] and in neurodevelopmental impair-
ment in 700 000 children per year [2]. Preventing GBS infec-
tion will likely reduce global NE incidence and mortality. IAP 
may go some way to reduce infection but will not always be 
implemented prior to in utero infection/inflammation onset. 
More important, IAP is not available to all women around the 
world. For these reasons, maternal vaccination against GBS is 
endorsed.
CONCLUSIONS
This meta-analysis highlights the importance of recogniz-
ing GBS infection in infants with NE. The proportion of term 
infants with NE and coexisting GBS infection is >10 times that 
seen among term infants without NE. Mortality rate among 
infants with GBS-associated NE is close to double that of infants 
with NE without GBS. The final estimate of GBS invasive disease 
in association with NE is limited to a subset of encephalopathic 
infants in high-resource settings, fulfilling criteria for therapeu-
tic hypothermia, and is therefore likely an underestimation of 
the global situation, especially in low-resource settings where 
access to intrapartum care is lacking. Robust follow-up data were 
not available to determine the impact of GBS infection in combi-
nation with NE on long-term survival and neurodevelopmental 
impairment. To ascertain the full extent of the burden of disease, 
data gaps must be addressed, including long term follow-up of 
NE survivors, especially those with infection, and increased data 
from LMICs. The increased mortality rate in GBS-associated NE 
is unlikely to be completely addressed by IAP and may be more 
effectively prevented by maternal vaccination (Table 5).
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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